| Autor: |
de Boer MGJ; LUMC, afd. Infectieziekten, Leiden.; Contact: Mark G.J. de Boer (m.g.j.de_boer@lumc.nl)., Gieling EM; UMC Utrecht, afd. Klinische Farmacie, Utrecht., van der Linden PD; Tergooi, afd. Klinische Farmacie, Hilversum., Sinha BNM; UMCG, afd. Medische Microbiologie en Infectiepreventie, Groningen., Vollaard AM; RIVM, Centrum Infectieziektebestrijding, Bilthoven. |
| Jazyk: |
Dutch; Flemish |
| Zdroj: |
Nederlands tijdschrift voor geneeskunde [Ned Tijdschr Geneeskd] 2020 Nov 12; Vol. 164. Date of Electronic Publication: 2020 Nov 12. |
| Abstrakt: |
Much has changed in the medical treatment of COVID-19 after the first patient with an infection with SARS-CoV-2 in the Netherlands was diagnosed in February 2020. On the basis of limited data, at first only off-label use of (hydroxy)chloroquine seemed to be a treatment option. However, now based on the findings of several randomized studies, other medicines have been included in the Dutch guidelines about the treatment of COVID-19. In this article, we will briefly discuss the current state of affairs with regard to the drugs (hydroxy) chloroquine, remdesivir and corticosteroids. Again, it appears that only well-executed randomized clinical trials can determine the status of various supposedly effective drugs. |
| Databáze: |
MEDLINE |
| Externí odkaz: |
|
